Pacific Edge wins final Medicare coverage for Cxbladder Triage tests

Final Medicare policy confirms Cxbladder coverage

Pacific Edge Limited (NZX/ASX:PEB) has cleared the regulatory hurdle that has dominated its US recovery plan: Medicare will cover Cxbladder Triage and Triage Plus for intermediate-risk patients undergoing evaluation for microhematuria.

The final Local Coverage Determination, L40378, establishes hematuria evaluation as a covered Medicare benefit and is scheduled to take effect on 20 December 2026. Pacific Edge said the final policy closely resembles the draft published in May, limiting the remaining uncertainty around the scope of coverage.

Coverage creates a larger US reimbursement opportunity

Pacific Edge estimates the policy addresses roughly 1.14 million testing opportunities each year among intermediate-risk microhematuria patients. That is a management estimate rather than demonstrated demand, but the company says its two tests are the only products covered under the final LCD, with competing tests and generic billing codes listed as noncovered.

The decision follows the company's earlier draft Medicare coverage pathway, which framed Medicare reimbursement as the centrepiece of a proposed US recovery. The final policy now gives urologists a defined reimbursement basis for ordering the tests, removing one practical objection for clinicians who had been reluctant to use them without established Medicare coverage.

Higher test prices raise the stakes for adoption

Pacific Edge said Medicare reimbursement should support a higher average selling price and operating leverage. Under the stated PAMA pricing, Triage is priced at US$1,057 per test, Monitor at US$1,026 and Triage Plus at US$1,328. The company's stated strategy is to shift hematuria evaluation testing towards Triage Plus and concentrate on intermediate-risk patients.

That pricing opportunity is meaningful only if coverage converts into orders and collections. The LCD becomes effective next month, so the announcement does not yet show realised Medicare revenue, cash flow or the rate at which physicians will change their testing patterns.

Commercial payer expansion becomes the next test

Pacific Edge expects Medicare policy to strengthen negotiations with commercial payers and says Geisinger, owned by Kaiser Permanente, has recently established a commercial policy covering all-risk microhematuria patients. The company says its hematuria tests now have commercial contracts covering 12.9 million lives, in addition to Medicare's more than 71 million US beneficiaries.

Management also expects Medicare Advantage plans to reimburse in line with Medicare policy and said the company is making selective investments in its commercial team and digital technologies. The earlier recovery case included falling US commercial volumes, making execution particularly important: the next evidence will come from Medicare uptake, Triage Plus mix, average selling prices and the pace of additional payer decisions.